The Latest Breaking News from Catalyst Pharmaceuticals

This IBD 50 holding holds top notch ratings amid a market downturn.

On Friday, Catalyst Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 93 to 96.

Catalyst Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.

Catalyst Pharmaceuticals doubled earnings expectations amid a strong launch for its new drug, Agamree. The biotech stock jumped Thursday.

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future? Let’s look at its financial metrics to get an idea….